Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Recombinant human anti-PCSK9 monoclonal antibody(Tasly Pharmaceutical Group Co., Ltd.) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Recombinant human anti-PCSK9 monoclonal antibody(Tasly Pharmaceutical Group Co., Ltd.): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical de
9 min read
710GO Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
710GO: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Neoantigen mRNA Vaccine(Second Affiliated Hospital of Guangzhou Medical University): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical devel
9 min read
EL-2002 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
EL-2002: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
MVA strain monkeypox live attenuated vaccine(Shanghai Institute of Biological Products) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
MVA strain monkeypox live attenuated vaccine(Shanghai Institute of Biological Products): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical d
9 min read
Recombinant vectorized subunit vaccine(GSK) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
Recombinant vectorized subunit vaccine(GSK): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market posi
9 min read
GMA-131 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
GMA-131: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
AK157D1 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
AK157D1: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
KBP-0078 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
KBP-0078: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
PRO-147 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
PRO-147: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
ORIP-1001 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
ORIP-1001: Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, market position, and key risks.
9 min read
CD19/CD20/CD22 CAR-T (Baylor College of Medicine) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
29 September 2026
CD19/CD20/CD22 CAR-T (Baylor College of Medicine): Phase 1. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical development, IP, licensing deals, marke